Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

J. Paavonen, D. Jenkins, X.F. Bosch, P.D. Naud, J. Salmeron, C.M. Wheeler, S. Chow, D.L. Apter, H.C. Kitchener, X. Castellsague, N. S De Carvalho, Susan Skinner

    Research output: Contribution to journalArticlepeer-review

    1100 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)2161-70
    JournalThe Lancet
    Issue number9580
    Publication statusPublished - 2007

    Cite this